2023
The Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy
Hussain Y, Saito S, Curtis M, Kereiakes D, Baumbach A, Zidar J, McLaurin B, Dib N, Smits P, Díaz V, Cequier Á, Hofma S, Pietras C, Dressler O, Issever M, Windecker S, Leon M, Lansky A, Investigators I. The Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 100629. PMID: 39130696, PMCID: PMC11307614, DOI: 10.1016/j.jscai.2023.100629.Peer-Reviewed Original ResearchTarget lesion failureAcute coronary syndromeChronic coronary syndromePrimary end pointCoronary syndromeDP-EESClinical presentationMajor adverse cardiac eventsEnd pointAdverse cardiac eventsBiodegradable polymer DESPrevious revascularizationLesion failureCardiac eventsCurrent smokersIII trialsLess diabetesCCS groupStent thrombosisPatientsRelative safetyDurable polymerSyndromeMonthsInteraction P
2022
Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III
Garot P, Leon M, Saito S, Baumbach A, Kereiakes D, Windecker S, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Diaz V, McLaurin B, Cequier A, Hofma S, Dib N, Namiki A, Takahashi A, Kakuta T, Hirohata A, Lansky A. Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 2: 100515. PMID: 39132534, PMCID: PMC11308104, DOI: 10.1016/j.jscai.2022.100515.Peer-Reviewed Original ResearchDrug-eluting stentsDurable polymer everolimus-eluting stentsEverolimus-eluting stentsIII trialsLesion failureClinical outcomesMyocardial infarctionMajor adverse cardiac eventsVessel-related myocardial infarctionBiodegradable polymer drug-eluting stentsAdverse cardiac eventsOutcomes of patientsTarget lesion failureTarget lesion revascularizationLesion revascularizationCardiac eventsPatient characteristicsCardiac deathDES groupProcedural successStent thrombosisSubgroup analysisPatient outcomesNonsignificant trendEnrollment locationOutcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy
Patel K, Lansky A, Kereiakes D, Windecker S, Cristea E, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Díaz V, McLaurin B, Brogno D, Janssens L, Vrolix M, Gómez-Blázquez I, Sahul Z, Kabour A, Salido L, Cleman M, Saito S, Leon M, Baumbach A, Investigators I. Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100004. PMID: 39130138, PMCID: PMC11308031, DOI: 10.1016/j.jscai.2021.100004.Peer-Reviewed Original ResearchDrug-eluting stentsTarget lesion failureDP-EESComplex lesionsLesion failureAdverse eventsLesion complexityMajor adverse cardiac eventsSingle-blind clinical trialEnd pointAdverse cardiac eventsChronic coronary syndromePrimary end pointSecondary end pointsTarget lesion revascularizationTarget vessel failureComplex coronary lesionsPercutaneous coronary interventionEverolimus-eluting stentsDrug eluting stentsHigh rateLesion revascularizationCoronary syndromeCardiac eventsCoronary intervention
2005
Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction
Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tcheng JE, Mehran R, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, Stone GW. Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction. Circulation 2005, 111: 1611-1618. PMID: 15811868, DOI: 10.1161/01.cir.0000160362.55803.40.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionPrimary stentingAddition of abciximabBody surface areaCADILLAC trialMyocardial infarctionRisk factorsFemale genderIschemic target vessel revascularizationLower body surface areaMajor adverse cardiac eventsOverall adverse outcomesTIMI grade 3Adverse cardiac eventsTarget vessel revascularizationClinical risk factorsComorbid risk factorsInterventional treatment strategiesImportant independent determinantHigh mortality rateMACE ratePrimary angioplastyCardiac eventsSymptom onsetIndependent predictors